Trillium Therapeutics Inc.

Trillium Therapeutics Inc. (NASDAQ:TRIL) shares lost almost half of their value today, after initial data for the company’s lead cancer drug TTI-621, which were released this morning in an ASH abstract, raised safety concerns.

However, Cowen analyst Boris Peaker remains bullish, reiterating an Outperform rating on the stock.

Peaker explained, “Safety concerns (DLT of thrombocytopenia) have caused a marked selloff which we believe is unwarranted given this is Phase I dose-escalation trial. TRIL has advanced this study into expansion arms which we believe indicates they have found a therapeutic window.”

“At ASH we expect additional data from approximately 10 more patients at the 0.2 mg/kg dose, as well as PK/PD data. TRIL expects initial solid tumor data to become available in late 2017,” the analyst added.

As usual, we like to include the analyst’s trackrecord when reporting on new analyst notes. According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Boris Peaker has a yearly average return of 6.4% and a 38.5% success rate. Peaker has a 33% average return when recommending TRIL, and is ranked #457 out of 4165 analysts.

As of this writing, all the 3 analysts polled by TipRanks, in the past 3 months, rate Trillium Therapeutics stock a Buy. With a return potential of nearly 207%, the stock’s consensus target price stands at $23.67.

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. (NASDAQ:PTCT) shares tumbled over 30% today after the company disclosed in its earnings call that ongoing discussions with EU regulators have introduced “a higher degree of uncertainty” regarding an outcome for Translarna, the company’s Duchenne muscular dystrophy (DMD) drug.

Cowen analyst Ritu Baral noted, “While Translarna sales remain strong in the EU, we note substantial uncertainty in its regulatory path forward in both the US and EU. We expect an update on both regulatory proceedings by YE2016. In addition, we await clinical data from the cystic fibrosis program in late 1Q17 and note early progress in the Roche-partnered SMA program.”

As such, Baral reiterates a Market Perform rating on shares of PTC Therapeutics, without providing a price target.

According to TipRanks.com, analyst Ritu Baral has a yearly average loss of 0.3% and a 31% success rate. Baral has a 69.5% average loss when recommending PTCT, and is ranked #2731 out of 4165 analysts.

Out of the 10 analysts polled by TipRanks, 8 rate PTC Therapeutics stock a Hold, while 2 rate the stock a Buy. With a return potential of 197%, the stock’s consensus target price stands at $12.